Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer

Pharmacotherapy

Volumn 29, Issue 12, 2009, Pages 1482-1490

  Barnett, Chad M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracycline resistance; Metastatic breast cancer; Overall survival; Progression free survival; Taxane resistance

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; IXABEPILONE; LAPATINIB; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; GOLD STANDARD; HUMAN; LOADING DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 73349139872     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.12.1482     Document Type: Review

References (35)

1. . U.S. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. May 2007. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceR egulatoryInformation/Guidances/UCM071590.pdf. Accessed October 2, 2009.
2. . Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003;21:2045-7.
3. . Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008;99:1572-8.
4. . Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008;8:224-33.
5. . Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92.
6. . Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs combined therapy results from a MOSG randomized phase III trial [abstract]. J Clin Oncol 2006;24(suppl 18):abstract 570.
7. . Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(suppl 1):S9-15.
8. . Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
9. . Dumontet C, Jordan M, Lee F. Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009;8:17-25.
10. . Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-15.
11. . Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as firstline chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 2002;20:3114-21.
12. . Nabholtz JM, Falkson C, Campos D, et al, for the TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75.
13. . Bontenbal M, Creemers GJ, Braun HJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol 2005;23:7081-8.
14. . Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom national cancer research institute trial AB01. J Clin Oncol 2005;23:8322-30.
15. . Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51.
16. . Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
17. . Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
18. . Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893-901.
19. . Martin M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish breast cancer research group (GEICAM) trial. Lancet Oncol 2007;8:219-25.
20. . Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25: 5210-17.
21. . Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. Presented at the American Society of Clinical Oncology (ASCO) breast cancer symposium, Washington, DC, September 5-7, 2008.
22. . Von Minckwitz G, Du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast cancer group 26/breast cancer international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
23. . Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
24. . O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol 2008;26(suppl):abstract 1015.
25. . Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
26. . Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy: 304 study group. J Clin Oncol 1999;17:1413-24.
27. . Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-15.
28. . Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358: 1663-71.
29. . Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92.
30. . Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 2008;26:1642-9.
31. . Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer 2008;8(suppl 2):S61-70.
32. . O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
33. . Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment [letter]. J Clin Oncol 2008;26:2223.
34. . Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
35. . Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.